Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00800839 · OUTCOME

2-year Progression-Free Survival

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide · Source last updated 2016-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
First 25-35 days post transplant and then every 3 months for a maximum of 2 years

What was measured

Progression-free survival (PFS) is defined as the interval between day of transplant and day of death or disease progression.

Groups in this outcome

Busulfan + Fludarabine + Cyclophosphamide

Busulfan starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Busulfan + Fludarabine + Cyclophosphamide49

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Busulfan + Fludarabine + Cyclophosphamide26Not reported1539Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        15
        upper Limit
        39
        value
        26
denoms
  1. counts
    1. group Id
      OG000
      value
      49
    units
    Participants
description
Progression-free survival (PFS) is defined as the interval between day of transplant and day of death or disease progression.
dispersion Type
95% Confidence Interval
groups
  1. description
    Busulfan starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
    id
    OG000
    title
    Busulfan + Fludarabine + Cyclophosphamide
param Type
NUMBER
reporting Status
POSTED
time Frame
First 25-35 days post transplant and then every 3 months for a maximum of 2 years
title
2-year Progression-Free Survival
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice